Glutamic acid decarboxylase antibodies in neurocritical patients: a culprit or a bystander?
Dongmei WangKaibin HuangZhenzhou LinYongfang ZhangGuanghui LiuYongming WuShengnan WangPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
Most neurocritical patients with serologically positive GAD-Abs had other specific autoimmune antibodies. All patients responded well to immunotherapy, but not parallel to the titers of GAD-Abs. These results indicated that GAD-Abs might be more a bystander than a culprit in neurocritical patients, suggesting that an underlying autoimmune disease should be explored.